Pin11 Cost Analysis of Adverse Drug Events Grom Gpo-Vir®s and Gpo-Vir®z in People Living With Hiv/Aids in Thailand

Srimongkon, Pornchanok; Supakul, Sopak; Lucksiri, Aroonrut; Permsuwan, Unchalee

doi:10.1016/s1098-3015(11)73291-0

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean direct medical cost of an ADR episode was USD 44 (THB 1,490) in both groups, USD 60 (THB 2,053) in the GPO-VIR S group, and USD 12 (THB 410) in the GPO-VIR Z group. 26 In India, Radhakrishnan et al demonstrated that direct costs of ADRs to HAART in 110 HIV-infected hospitalized patients were USD 186, including costs of medication, medical supply, laboratory investigation, and services. 27 In Spain, Homar et al determined costs of ADRs for 75 patients treated with fix dosage combinations and 150 patients treated with combinations of separately administered antiretroviral drugs from a single Spanish hospital.…”

Section: Discussionmentioning

confidence: 99%

Costs Associated with Adverse Drug Reactions Among HIV/TB Patients in Thailand

Rochanathimoke¹,

Tragulpiankit²,

Turongkaravee³

et al. 2022

CEOR

View full text Add to dashboard Cite

Purpose To assess the direct and indirect costs associated with adverse drug reactions (ADRs) in patients receiving treatment regimens for human immunodeficiency virus (HIV) infection and tuberculosis (TB) in selected Thai hospitals. Patients and Methods This was a retrospective study conducted between October 2014 and September 2019 at three public hospitals in Thailand. Data were obtained from a medical database and spontaneous ADR reporting system of each study site. The out-of-pocket health payments and indirect costs were determined via interviewing. All costs were updated to 2021. Results A total of 432 eligible patients who experienced ADRs due to HIV and TB treatment, and 93 patients were interviewed to determine direct non-medical and indirect costs. The average direct medical cost for ADR was USD 5.65 for mild cases, USD 156.54 for moderate cases, and USD 1,242.45 for severe cases. For direct non-medical costs, the average cost per episode was USD 27.29 in mild ADR, USD 70.86 in moderate ADR and USD 270.66 in severe ADR. The indirect cost incurred in each mild, moderate and severe ADR was USD 41.86, USD 89.34, and USD 552.60, respectively. The Stevens-Johnson syndrome (SJS) had the highest management costs. Conclusion ADRs associated with anti-tuberculosis drugs and antiretroviral drugs seem to have a substantial economic impact from a societal perspective. These findings would be useful for increasing awareness and encouraging early avoidance of ADRs.

show abstract

Section: Discussionmentioning

confidence: 99%